At Uteron pharma we are committed to enabling (cutting-edge scientific) research that is driven by the women’s needs.
Our mission is to help improve overall healthcare and everyday lives of women. We focus on providing high value products relating to (i) Contraception and fertility (ii) Menopause and osteoporosis (iii) Utero-vaginal sphere and (iv) Female cancer
Our diversified development portfolio includes a new generation of oral contraceptives based on natural hormones, a hormonal intra-uterine device, treatments for persistent vaginal infections and a new generation of tests that will significantly increase in-vitro fertilisation success rates. Based on a silicone based technology platform, Uteron also develops sustained or controlled release devices for well known hormones.
It is the intention of Uteron to market its products worldwide through a network of partners as soon as its products have been approved by the appropriate health authorities. Uteron, headquartered in Liege (Belgium), is a privately-owned group of companies.